JP2023540797A5 - - Google Patents
Info
- Publication number
- JP2023540797A5 JP2023540797A5 JP2023516057A JP2023516057A JP2023540797A5 JP 2023540797 A5 JP2023540797 A5 JP 2023540797A5 JP 2023516057 A JP2023516057 A JP 2023516057A JP 2023516057 A JP2023516057 A JP 2023516057A JP 2023540797 A5 JP2023540797 A5 JP 2023540797A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- nucleic acid
- endonuclease
- acid editing
- manipulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077057P | 2020-09-11 | 2020-09-11 | |
| US63/077,057 | 2020-09-11 | ||
| US202163222351P | 2021-07-15 | 2021-07-15 | |
| US63/222,351 | 2021-07-15 | ||
| PCT/US2021/049962 WO2022056324A1 (en) | 2020-09-11 | 2021-09-10 | Base editing enzymes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540797A JP2023540797A (ja) | 2023-09-26 |
| JP2023540797A5 true JP2023540797A5 (enExample) | 2024-09-13 |
Family
ID=80629930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516057A Pending JP2023540797A (ja) | 2020-09-11 | 2021-09-10 | 塩基編集酵素 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US12286654B2 (enExample) |
| EP (1) | EP4211234A4 (enExample) |
| JP (1) | JP2023540797A (enExample) |
| KR (1) | KR20230062873A (enExample) |
| AU (1) | AU2021339819A1 (enExample) |
| CA (1) | CA3192224A1 (enExample) |
| GB (1) | GB2605340B (enExample) |
| MX (1) | MX2023002913A (enExample) |
| WO (1) | WO2022056324A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178933A2 (en) | 2020-03-06 | 2021-09-10 | Metagenomi Ip Technologies, Llc | Class ii, type v crispr systems |
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| JP7646552B2 (ja) | 2019-01-31 | 2025-03-17 | ビーム セラピューティクス インク． | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| WO2020168135A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| US10913941B2 (en) | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| CA3177051A1 (en) * | 2020-03-31 | 2021-10-07 | Metagenomi, Inc. | Class ii, type ii crispr systems |
| CA3192224A1 (en) | 2020-09-11 | 2022-03-17 | Jyun-Liang LIN | Base editing enzymes |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| KR20230134543A (ko) * | 2021-01-22 | 2023-09-21 | 메타지노미, 인크. | 신규한 조작된 뉴클레아제 및 키메라 뉴클레아제 |
| CN119452085A (zh) | 2021-08-27 | 2025-02-14 | 宏基因组学公司 | 具有ruvc结构域的酶 |
| MX2024005505A (es) * | 2021-11-05 | 2024-05-23 | Metagenomi Inc | Enzimas de edicion de bases. |
| KR20240110603A (ko) | 2021-11-24 | 2024-07-15 | 메타지노미, 인크. | 엔도뉴클레아제 시스템 |
| CN121241133A (zh) * | 2023-03-31 | 2025-12-30 | 阿伯生物技术公司 | Crispr核酸酶多肽和包含此类crispr核酸酶多肽的基因编辑系统 |
| WO2025003344A1 (en) * | 2023-06-28 | 2025-01-02 | Alia Therapeutics Srl | Type ii cas proteins and applications thereof |
| WO2025106894A1 (en) * | 2023-11-15 | 2025-05-22 | Profluent Bio Inc. | Adenine deaminases and compositions, systems, and methods thereof |
| WO2025240372A1 (en) * | 2024-05-13 | 2025-11-20 | Metagenomi, Inc. | Compositions and methods for editing t cells |
| WO2026143185A1 (en) | 2024-12-23 | 2026-07-02 | Ensoma Aps | Engineered rna-guided dna-binding polypeptides |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018027078A1 (en) * | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| US11192929B2 (en) | 2016-12-08 | 2021-12-07 | Regents Of The University Of Minnesota | Site-specific DNA base editing using modified APOBEC enzymes |
| CN110234770A (zh) | 2017-01-17 | 2019-09-13 | 基础科学研究院 | 通过dna单链断裂识别碱基编辑脱靶位点的方法 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| CN110892069B (zh) * | 2017-03-30 | 2024-02-09 | 国立大学法人京都大学 | 基于基因组编辑的外显子跳跃诱导方法 |
| US9982279B1 (en) * | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| CN111328290A (zh) * | 2017-06-26 | 2020-06-23 | 博德研究所 | 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法 |
| CA3084825A1 (en) * | 2017-12-14 | 2019-06-20 | Crispr Therapeutics Ag | Novel rna-programmable endonuclease systems and their use in genome editing and other applications |
| WO2020163396A1 (en) * | 2019-02-04 | 2020-08-13 | The General Hospital Corporation | Adenine dna base editor variants with reduced off-target rna editing |
| KR20240007322A (ko) | 2019-02-14 | 2024-01-16 | 메타지노미, 인크. | Ruvc 도메인이 존재하는 효소 |
| CN113728097A (zh) | 2019-02-14 | 2021-11-30 | 宏基因组学知识产权技术有限责任公司 | 具有ruvc结构域的酶 |
| US20220403357A1 (en) | 2019-11-12 | 2022-12-22 | The Broad Institute, Inc. | Small type ii cas proteins and methods of use thereof |
| CA3177051A1 (en) * | 2020-03-31 | 2021-10-07 | Metagenomi, Inc. | Class ii, type ii crispr systems |
| CA3192224A1 (en) | 2020-09-11 | 2022-03-17 | Jyun-Liang LIN | Base editing enzymes |
| GB202418708D0 (en) | 2020-09-11 | 2025-02-05 | Metagenomi Inc | Base editing enzymes |
| MX2024005505A (es) * | 2021-11-05 | 2024-05-23 | Metagenomi Inc | Enzimas de edicion de bases. |
-
2021
- 2021-09-10 CA CA3192224A patent/CA3192224A1/en active Pending
- 2021-09-10 KR KR1020237012244A patent/KR20230062873A/ko active Pending
- 2021-09-10 JP JP2023516057A patent/JP2023540797A/ja active Pending
- 2021-09-10 EP EP21867718.5A patent/EP4211234A4/en active Pending
- 2021-09-10 GB GB2209534.3A patent/GB2605340B/en active Active
- 2021-09-10 WO PCT/US2021/049962 patent/WO2022056324A1/en not_active Ceased
- 2021-09-10 AU AU2021339819A patent/AU2021339819A1/en active Pending
- 2021-09-10 MX MX2023002913A patent/MX2023002913A/es unknown
-
2022
- 2022-06-15 US US17/841,082 patent/US12286654B2/en active Active
-
2023
- 2023-03-07 US US18/180,009 patent/US20230348876A1/en active Pending
- 2023-05-31 US US18/326,440 patent/US20230374482A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519953A5 (enExample) | ||
| JP7788744B2 (ja) | Ｃａｓ９ターゲッティングをガイドする配列に関する方法および組成物 | |
| JP2023517041A5 (enExample) | ||
| US11702643B2 (en) | System and method for genome editing | |
| JP2022520428A5 (enExample) | ||
| FI4118198T3 (fi) | Rna-ohjattuja nukleaaseja ja niiden aktiivisia fragmentteja ja variantteja ja käyttömenetelmiä | |
| JP2023126956A (ja) | 望ましくないオフターゲット塩基エディター脱アミノ化を制限するためのスプリットデアミナーゼの使用 | |
| AU2025275207A1 (en) | Variants of CRISPR from Prevotella and Francisella 1 (Cpf1) | |
| JP2024541402A5 (enExample) | ||
| US10093910B2 (en) | Engineered CRISPR-Cas9 nucleases | |
| JP2022519507A5 (enExample) | ||
| JP2023541400A5 (enExample) | ||
| JP2023549339A5 (enExample) | ||
| JP2023520504A5 (enExample) | ||
| JP2021518139A5 (enExample) | ||
| GB2587970A (en) | Compositions and methods for gene editing | |
| IL321024A (en) | Engineered CAS9 Systems For Eukaryotic Genome Modification | |
| EP3341477A1 (en) | Engineered crispr-cas9 nucleases | |
| JP2021532815A5 (enExample) | ||
| JP2020532967A (ja) | 変更されたＰＡＭ特異性を有する遺伝子操作されたＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ | |
| JP2023516226A5 (enExample) | ||
| JP2021526858A5 (enExample) | ||
| JP2019536462A5 (enExample) | ||
| JP2025505732A5 (enExample) | ||
| US20250154513A1 (en) | Applications of Streptococcus-derived Cas9 nucleases on minimal Adenine-rich PAM targets |